Anticancer Effect of Cisplatin-Loaded Poly (Butylcyanoacrylate) Nanoparticles on A172 Brain Cancer Cells Line

pH-responsive cisplatin-loaded niosomes: synthesis, characterization, cytotoxicity study and interaction analyses by simulation methodology

Cisplatin (Cis) is an effective cytotoxic agent, but its administration has been challenged by kidney problems, reduced immunity system, chronic neurotoxicity, and hemorrhage. To address these issues, pH-responsive non-ionic surfactant vesicles (niosomes) by Span 60 and Tween 60 derivatized by cholesteryl hemisuccinate (CHEMS), a pH-responsive agent, and Ergosterol (helper lipid), were developed for the first time to deliver Cis. The drug was encapsulated in the niosomes with a high encapsulation efficiency of 89%. This system provided a responsive release of Cis in pH 5.4 and 7.4, thereby improving its targeted anticancer drug delivery. The noisome bilayer model was studied by molecular dynamic simulation containing Tween 60, Span 60, Ergosterol, and Cis molecules to understand the interactions between the loaded drug and noisome constituents. We found that the platinum and chlorine atoms in Cis are critical factors in distributing the drug between water and bilayer surface. Finally, the lethal effect of niosomal Cis was investigated on the MCF7 breast cancer cell line using 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Results from morphology monitoring and cytotoxic assessments suggested a better cell-killing effect for niosomal Cis than standard Cis. Together, the synthesis of stimuli-responsive niosomes could represent a promising delivery strategy for anticancer drugs.

Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles

The prevalence of neurological/neurodegenerative diseases, such as Alzheimer's disease is known to be increasing due to an aging population and is anticipated to further grow in the decades ahead. The treatment of brain diseases is challenging partly due to the inaccessibility of therapeutic agents to the brain. An increasingly important observation is that the physiology of the brain alters during many brain diseases, and aging adds even more to the complexity of the disease. There is a notion that the permeability of the blood-brain barrier (BBB) increases with aging or disease, however, the body has a defense mechanism that still retains the separation of the brain from harmful chemicals in the blood. This makes drug delivery to the diseased brain, even more challenging and complex task. Here, the physiological changes to the diseased brain and aged brain are covered in the context of drug delivery to the brain using nanoparticles. Also, recent and novel approaches are discussed for the delivery of therapeutic agents to the diseased brain using nanoparticle based or magnetic resonance imaging guided systems. Furthermore, the complement activation, toxicity, and immunogenicity of brain targeting nanoparticles as well as novel in vitro BBB models are discussed.

Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy

Cisplatin and other platinum-based chemotherapeutic drugs have been used extensively for the treatment of human cancers such as bladder, blood, breast, cervical, esophageal, head and neck, lung, ovarian, testicular cancers, and sarcoma. Cisplatin is commonly administered intravenously as a first-line chemotherapy for patients suffering from various malignancies. Upon absorption into the cancer cell, cisplatin interacts with cellular macromolecules and exerts its cytotoxic effects through a series of biochemical mechanisms by binding to Deoxyribonucleic acid (DNA) and forming intra-strand DNA adducts leading to the inhibition of DNA synthesis and cell growth. Its primary molecular mechanism of action has been associated with the induction of both intrinsic and extrinsic pathways of apoptosis resulting from the production of reactive oxygen species through lipid peroxidation, activation of various signal transduction pathways, induction of p53 signaling and cell cycle arrest, upregulation of pro-apoptotic genes/proteins, and down-regulation of proto-oncogenes and anti-apoptotic genes/proteins. Despite great clinical outcomes, many studies have reported substantial side effects associated with cisplatin monotherapy, while others have shown substantial drug resistance in some cancer patients. Hence, new formulations and several combinational therapies with other drugs have been tested for the purpose of improving the clinical utility of cisplatin. Therefore, this review provides a comprehensive understanding of its molecular mechanisms of action in cancer therapy and discusses the therapeutic approaches to overcome cisplatin resistance and side effects.